AU Patent

AU2021379921A1 — Use of pharmaceutical doses of niacin, or an analog thereof, for the regression or reversal of fibrosis and/or liver cirrhosis

Assigned to US Department of Veterans Affairs · Expires 2023-07-06 · 3y expired

What this patent protects

The disclosure provides for the use of high-dose (pharmacologic) niacin, or a niacin analog thereof, for the treatment or regression of fibrosis or liver cirrhosis in a subject in need thereof.

USPTO Abstract

The disclosure provides for the use of high-dose (pharmacologic) niacin, or a niacin analog thereof, for the treatment or regression of fibrosis or liver cirrhosis in a subject in need thereof.

Drugs covered by this patent

Patent Metadata

Patent number
AU2021379921A1
Jurisdiction
AU
Classification
—
Expires
2023-07-06
Drug substance claim
No
Drug product claim
No
Assignee
US Department of Veterans Affairs
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.